Patient Guide: Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)≥1≤19.

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 8 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT06869473
Status: 🟢 Enrolling Now
Condition: Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Phase: PHASE2

Find a Study Location Near You

This study is available at 8 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Rozzano, Milano
  • Cagliari,
  • Catania,
  • • And 5 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily